P1012 Dose escalated Ustekinumab in Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights Program
Michael Barnett(The University of Sydney), Jane M. Andrews(Health Net), Judith McNamara(Liverpool Hospital), Graham Radford‐Smith(QIMR Berghofer Medical Research Institute), Kate D. Lynch(Royal Adelaide Hospital), Ian C. Lawrance(The University of Western Australia), Joseph L. Pipicella(Ingham Institute), Richard B. Gearry(Waitaki Biosciences (New Zealand)), Simon Ghaly(UNSW Sydney), Susan J. Connor(Liverpool Hospital), Jakob Begun(Translational Research Institute), Wayne H. Wilson(Lyell McEwin Hospital), Astrid‐Jane Williams, Gregor Walker(The University of Queensland), Michael Schultz
Cited by 0
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Maintenance Therapy with Certolizumab Pegol for Crohn's Disease
|New England Journal of Medicine|2007|1.1k